Rahul Nayak

Employment

• Emory University School of Medicine Fellow
  2022 - Present
• Massachusetts General Hospital Resident
  2019 - 2022
• National Institutes of Health Pre-doctoral Fellow
  2013 - 2015

Education

• Harvard Medical School MD
  2015 - 2019
• Duke University BSE
  2009 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• The high costs of anticancer therapies in the USA: challenges, opportunities and progress
  Nature Reviews Clinical Oncology 2024 DOI: 10.1038/s41571-024-00948-1
  +Save
• Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress
  Nature Reviews Clinical Oncology 2024 DOI: 10.1038/s41571-024-00958-z
  +Save
• SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
  Clinical lymphoma, myeloma & leukemia 2023 DOI: 10.1016/j.clml.2023.08.011
  +Save
• 340B-Where Do We Go From Here?
  JAMA 2023 DOI: 10.1001/jama.2023.11056
  +Save
• The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
  Current cardiology reports 2023 DOI: 10.1007/s11886-023-01878-7
  +Save
• Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act.
  JAMA cardiology 2023 DOI: 10.1001/jamacardio.2022.5033
  +Save
• Maintenance therapy for AML after allogeneic HCT.
  Frontiers in oncology 2022 DOI: 10.3389/fonc.2022.895771
  +Save
• Financial toxicity in cancer care: origins, impact, and solutions.
  Translational behavioral medicine 2021 DOI: 10.1093/tbm/ibab091
  +Save
• Public-sector Contributions to Novel Biologic Drugs.
  JAMA internal medicine 2021 DOI: 10.1001/jamainternmed.2021.3720
  +Save
• Public sector financial support for late stage discovery of new drugs in the United States: cohort study
  BMJ 2019 DOI: 10.1136/bmj.l5766
  +Save